Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA.
Department of Pharmacology and Molecular Science, Johns Hopkins University School of Medicine, Baltimore, MD.
J Immunol. 2021 May 15;206(10):2290-2300. doi: 10.4049/jimmunol.1901212. Epub 2021 Apr 28.
Siglec-8 is an inhibitory receptor expressed on eosinophils and mast cells. In this study, we took advantage of a novel Siglec-8 transgenic mouse model to assess the impact of modulating IgE-dependent mast cell degranulation and anaphylaxis using a liposomal platform to display an allergen with or without a synthetic glycan ligand for Siglec-8 (Sig8L). The hypothesis is that recruitment of Siglec-8 to the IgE-FcεRI receptor complex will inhibit allergen-induced mast cell degranulation. Codisplay of both allergen and Sig8L on liposomes profoundly suppresses IgE-mediated degranulation of mouse bone marrow-derived mast cells or rat basophilic leukemia cells expressing Siglec-8. In contrast, liposomes displaying only Sig8L have no significant suppression of antigenic liposome-induced degranulation, demonstrating that the inhibitory activity by Siglec-8 occurs only when Ag and Sig8L are on the same particle. In mouse models of anaphylaxis, display of Sig8L on antigenic liposomes completely suppresses IgE-mediated anaphylaxis in transgenic mice with mast cells expressing Siglec-8 but has no protection in mice that do not express Siglec-8. Furthermore, mice protected from anaphylaxis remain desensitized to subsequent allergen challenge because of loss of Ag-specific IgE from the cell surface and accelerated clearance of IgE from the blood. Thus, although expression of human Siglec-8 on murine mast cells does not by itself modulate IgE-FcεRI-mediated cell activation, the enforced recruitment of Siglec-8 to the FcεRI receptor by Sig8L-decorated antigenic liposomes results in inhibition of degranulation and desensitization to subsequent Ag exposure.
Siglec-8 是一种在嗜酸性粒细胞和肥大细胞上表达的抑制性受体。在这项研究中,我们利用一种新型 Siglec-8 转基因小鼠模型,评估了使用脂质体平台来展示过敏原和/或合成糖基配体 Siglec-8(Sig8L)来调节 IgE 依赖性肥大细胞脱颗粒和过敏反应的影响。假设是将 Siglec-8 募集到 IgE-FcεRI 受体复合物将抑制过敏原诱导的肥大细胞脱颗粒。在脂质体上共展示过敏原和 Sig8L 可显著抑制表达 Siglec-8 的小鼠骨髓来源肥大细胞或大鼠嗜碱性白血病细胞的 IgE 介导的脱颗粒。相比之下,仅显示 Sig8L 的脂质体对抗原性脂质体诱导的脱颗粒没有明显的抑制作用,表明 Siglec-8 的抑制活性仅在 Ag 和 Sig8L 位于同一颗粒上时才会发生。在过敏反应的小鼠模型中,在表达 Siglec-8 的肥大细胞的转基因小鼠中,抗原性脂质体上显示 Sig8L 可完全抑制 IgE 介导的过敏反应,但在不表达 Siglec-8 的小鼠中没有保护作用。此外,由于 Ag 特异性 IgE 从细胞表面丢失和 IgE 从血液中清除加速,从过敏反应中得到保护的小鼠仍然对随后的过敏原挑战脱敏。因此,尽管人类 Siglec-8 在小鼠肥大细胞上的表达本身不会调节 IgE-FcεRI 介导的细胞激活,但 Sig8L 修饰的抗原性脂质体强制招募 Siglec-8 到 FcεRI 受体导致脱颗粒抑制和随后的 Ag 暴露脱敏。